Guidelines on the use of therapeutic apheresis in clinical practice—evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …

J Schwartz, JL Winters, A Padmanabhan… - Journal of clinical …, 2013 - Wiley Online Library
The American Society for Apheresis (ASFA) JCA Special Issue Writing Committee is
charged with reviewing, updating and categorizating indications for therapeutic apheresis …

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

M Noris, J Caprioli, E Bresin, C Mossali… - Clinical Journal of the …, 2010 - journals.lww.com
Background and objectives: Hemolytic uremic syndrome (HUS) is characterized by
microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment. Most …

[HTML][HTML] Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial

F Fakhouri, M Hourmant, JM Campistol… - American journal of …, 2016 - Elsevier
Background Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening
disease of chronic uncontrolled complement activation leading to thrombotic …

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

F Fakhouri, M Scully, F Provôt, M Blasco… - Blood, The Journal …, 2020 - ashpublications.org
Pregnancy and postpartum are high-risk periods for different forms of thrombotic
microangiopathy (TMA). However, the management of pregnancy-associated TMA remains …

Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice

N Knoers, C Antignac, C Bergmann… - Nephrology Dialysis …, 2022 - academic.oup.com
The overall diagnostic yield of massively parallel sequencing–based tests in patients with
chronic kidney disease (CKD) is 30% for paediatric cases and 6–30% for adult cases. These …

Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome

M Lemaire, V Frémeaux-Bacchi, F Schaefer, M Choi… - Nature …, 2013 - nature.com
Pathologic thrombosis is a major cause of mortality. Hemolytic-uremic syndrome (HUS)
features episodes of small-vessel thrombosis resulting in microangiopathic hemolytic …

[HTML][HTML] Membranoproliferative glomerulonephritis—a new look at an old entity

S Sethi, FC Fervenza - New England Journal of Medicine, 2012 - Mass Medical Soc
This review discusses the causes, pathogenesis, and clinical management of
membranoproliferative glomerulonephritis, which accounts for 7 to 10% of biopsy-confirmed …

[HTML][HTML] Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome

LA Greenbaum, M Fila, G Ardissino, SI Al-Akash… - Kidney international, 2016 - Elsevier
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …

[HTML][HTML] Heme on innate immunity and inflammation

FF Dutra, MT Bozza - Frontiers in pharmacology, 2014 - frontiersin.org
Heme is an essential molecule expressed ubiquitously all through our tissues. Heme plays
major functions in cellular physiology and metabolism as the prosthetic group of diverse …

A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury

S Jodele, BL Laskin, CE Dandoy, KC Myers, J El-Bietar… - Blood reviews, 2015 - Elsevier
Hematopoietic stem cell transplantation (HSCT)-associated thrombotic microangiopathy (TA-
TMA) is now a well-recognized and potentially severe complication of HSCT that carries a …